Pembrolizumab (Keytruda®). HTA ID: 23056

Assessment Status Full HTA submission received from Applicant
HTA ID 23056
Drug Pembrolizumab
Brand Keytruda®
Indication Pembrolizumab (Keytruda®) In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1.
Assessment Process
Rapid review commissioned 07/09/2023
Rapid review completed 03/10/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/11/2023
Pre-submission consultation with Applicant 05/12/2023
Full submission received from Applicant 02/05/2024